GlassScriptPhysician profile
Eric Scott Siegel
NPI 1275578262
$4,101.00
in general payments reported to CMS, 2019-2025
33 companies · $1,465 in 2025
The $1,465 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $698 · 2020: $310 · 2021: $360 · 2022: $180 · 2023: $525 · 2024: $563 · 2025: $1,465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,523 · Education: $30.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,523.06 |
| Education | $30.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $798.23 | 2019-2025 | Adbry, Anzupgo |
| Abbvie INC. | $546.17 | 2021-2025 | Rinvoq, Skyrizi |
| Pfizer INC. | $541.79 | 2019-2025 | |
| Janssen Biotech, INC. | $300.62 | 2019-2025 | Tremfya, Simponi, Stelara |
| Genzyme Corporation | $251.59 | 2021-2025 | |
| Galderma Laboratories, L.P. | $188.54 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Dermavant Sciences, INC. | $170.19 | 2022-2024 | Vtama |
| Lilly USA, LLC | $162.21 | 2019-2025 | Ebglyss, Olumiant, Taltz |
| Amgen INC. | $145.45 | 2021-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $130.32 | 2021-2025 | |
| Botanix Sb INC | $106.91 | 2025 | Sofdra |
| Incyte Corporation | $106.24 | 2023-2025 | Opzelura |
| Allergan, INC. | $70.38 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $68.94 | 2019-2025 | Libtayo, Dupixent |
| Sandoz INC. | $63.01 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $55.94 | 2019-2023 | Winlevi, Ilumya |
| Encore Dermatology INC. | $55.42 | 2019 | |
| Celgene Corporation | $45.50 | 2019-2024 | Sotyktu |
| Mayne Pharma Commercial LLC | $43.93 | 2020-2023 | |
| Arcutis Biotherapeutics, INC. | $33.22 | 2024-2025 | Zoryve |
| Almirall LLC | $31.86 | 2025 | Klisyri |
| Vyne Pharmaceuticals INC. | $24.12 | 2020 | |
| Organon LLC | $18.98 | 2025 | Vtama |
| Revance Therapeutics, INC. | $18.97 | 2024 | Daxxify |
| Journey Medical Corporation | $18.38 | 2025 | |
| Glaxosmithkline, LLC. | $15.28 | 2024 | Nucala |
| Mission Pharmacal Company | $14.29 | 2019 | |
| Ucb, INC. | $14.12 | 2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.40 | 2022 | |
| Sebela Pharmaceuticals INC. | $12.32 | 2019 | |
| Biofrontera INC. | $11.90 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Epi Health, LLC | $11.79 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $10.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Siegel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.